Next Article in Journal
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019
Previous Article in Journal
Investigation of Nano-Bio Interactions within a Pancreatic Tumor Microenvironment for the Advancement of Nanomedicine in Cancer Treatment
Case Report

An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)

1
Department of Clinical and Molecular Medicine, Oncology Unit, Sant’ Andrea Hospital, University “La Sapienza”, 00167 Rome, Italy
2
Department of Medical-Surgical Sciences and Translation Medicine, Sant’ Andrea Hospital, University “La Sapienza”, 00167 Rome, Italy
3
Oncology Unit, Istituto Dermopatico Dell’Immacolata—Istituti di Ricovero e Cura a Carattere Scientifico of Rome, 00167 Rome, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1980-1987; https://doi.org/10.3390/curroncol28030184
Received: 17 March 2021 / Revised: 12 May 2021 / Accepted: 16 May 2021 / Published: 25 May 2021
(This article belongs to the Special Issue Long-Term Effects of Systemic Therapies on Cancer Patients)
Background. Personalized therapy is becoming increasingly popular in oncological scenarios, not only based on molecular pharmacological targets, but also preventing any drug–drug–gene interaction (DDGI), which could lead to severe toxicities. Single nucleotide polymorphisms (SNPs), the individual germline sequence variations in genes involved in drug metabolism, are correlated to interindividual response to drugs and explain both efficacy and toxicity profiles reported by patients. Case presentation. We present the case of a woman suffering from triple-positive breast cancer; she had early-stage disease at the onset and after four years developed metastatic disease. During her history, she presented different toxicities due to antineoplastic treatments. Particularly, hypertransaminasemia was found during every line of treatment. Nevertheless, we were able to guarantee the patient an excellent therapeutic adhesion thanks to the supportive treatments and the reduction of drug dosage. Moreover, we conducted a simultaneous analysis of the patient’s biochemical and genomic data thanks to Drug-PIN software, and we found several significant SNPs of the main enzymes and transporters involved in drug metabolism. Conclusion. Our case report demonstrated the relevance of DDGI in clinical practice management of a patient treated for advanced breast cancer, suggesting the role of Drug-PIN software as an easy-to-use tool to prevent adverse events during cancer treatment and to help physicians in therapeutic algorithms. However, further studies are needed to confirm these results. View Full-Text
Keywords: hormone receptor positive (HR+); HER2+ breast cancer; drug-drug-gene interaction (DDGI); single nucleotide polymorphisms (SNPs) hormone receptor positive (HR+); HER2+ breast cancer; drug-drug-gene interaction (DDGI); single nucleotide polymorphisms (SNPs)
Show Figures

Figure 1

MDPI and ACS Style

Panebianco, M.; Taurelli Salimbeni, B.; Roberto, M.; Marchetti, P. An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report). Curr. Oncol. 2021, 28, 1980-1987. https://doi.org/10.3390/curroncol28030184

AMA Style

Panebianco M, Taurelli Salimbeni B, Roberto M, Marchetti P. An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report). Current Oncology. 2021; 28(3):1980-1987. https://doi.org/10.3390/curroncol28030184

Chicago/Turabian Style

Panebianco, Martina; Taurelli Salimbeni, Beatrice; Roberto, Michela; Marchetti, Paolo. 2021. "An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)" Curr. Oncol. 28, no. 3: 1980-1987. https://doi.org/10.3390/curroncol28030184

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop